Who We Are

Dr. Bogen is a Board-Certified Clinical Pathologist, having graduated from the University of Chicago Pritzker School of Medicine (M.D.) and the Weizman Institute of Science (Ph.D.), with a post-graduate residency and research fellowship at the Brigham and Women’s Hospital. He is Adjunct Professor of Pathology and Laboratory Medicine at Tufts University School of Medicine and Medical Director, Clinical Chemistry Laboratory (part-time) at Tufts Medical Center. Dr. Bogen is an inventor on 22 patents, all of which relate to various medical diagnostic technologies. In addition, he served for a decade on several NIH grant review committees, mainly for the Innovative Molecular Analysis of Cancer Technologies program sponsored by the National Cancer Institute. Dr. Bogen was previously the founder of CytoLogix Corporation, which developed the Artisan® instrument system for automated complex histopathology stains (now sold and supported by Agilent Corporation).

Ms. Vani is a co-founder of BCS. She has over 20 years of laboratory experience in biochemistry, molecular biology, and histology. Vani has operational responsibilities for BCS’s cGMP manufacturing processes and document control system in compliance with policies and SOPs. After receiving a Masters degree in Chemistry, she initially worked in Drosophila genetics, gaining experience in the field of molecular biology at Columbia University, New York NY. She later joined the R&D at CytoLogix Corp., Cambridge MA. She is a co-author on numerous peer-reviewed journal articles.

Scott brings 20 years of experience in the immunohistochemistry and molecular diagnostic branches of the Pathology Laboratory. Scott began his career with other members of the Boston Cell Standards team at Cytologix, and then went on to work at Dako and as an original member of the Vision Biosystems North American team, later acquired by Leica (Danaher). Scott has worked for several VC-backed start-up companies in the molecular diagnostics space, and most recently was Global Vice President of Sales, Service, and Field Support at Biocare Medical. Scott received a BS in Chemistry and a BA in English/Journalism from the University of Delaware.

Raisa is a results-driven quality and regulatory leader with over 20 years experience in biotechnology, life sciences, and diagnostics. Her career includes progressive leadership roles at Pacific Biosciences, Bio-Rad Laboratories, Digene, and Applied Biosystems where she implemented compliant, lean methodologies that accelerate product delivery and promote innovation. Raisa has also contributed to advancement of the profession through academia and industry service.  She was an affiliate professor with University of Washington’s Biomedical Regulatory Affairs Master’s Program and served on multiple certification exam committees under the American Society for Quality (ASQ). She earned a BS in Engineering from Miami University and maintains several professional ASQ certifications.

Tomasz Piech brings over two decades of experience in software engineering and biotechnology to his role as Chief Technology Officer at Boston Cell Standards. With a background spanning advanced imaging, machine vision, and data analytics, Tomasz has led the design and commercialization of cutting-edge diagnostic devices from concept to market. He has held senior engineering leadership roles at Quanterix and Quantum Diamond Technologies, founded a successful biotech software consultancy, and contributed to numerous peer-reviewed publications in biomedical technology. Tomasz holds a B.S. in Biological Engineering and Computer Science as well as an M.Eng. in Computer Science from Cornell University.

Rob brings nearly three decades of experience in a technology start-up involving rapid and significant growth in revenues. He was a co-founder and initial CEO of Torrent Systems, a start-up developing innovative technology for highly scalable data processing. Rob was deeply involved in the business for more than two decades, guiding product direction, technical sales, customer acquisition, and marketing messaging through two acquisitions. During this period, the software evolved into the industry’s leading enterprise data integration platform (IBM Information Server). Revenues generated from this platform grew from $0 initially to more than $20 billion cumulatively during this period. Rob holds an A.B. degree in economics from Dartmouth College and an MBA in finance and marketing from Chicago Booth.